Hepatitis C Good Practice Roadshow
Monday, 18 May 2015 10:44
Hepatitis C is a major cause of the UK’s rise in mortality from liver disease, and represents a serious health inequality issue that predominantly affects disadvantaged and marginalised groups. Raising awareness, diagnosing and treating more people with hepatitis C, especially in areas of high prevalence such as London - will be key to addressing health inequalities across the country and reducing costs to the NHS resulting from HCV-related liver disease. CCGs have a crucial role to play in ensuring this happens. With the aim of encouraging local service improvements and seizing the opportunity for progress provided by a new generation of highly effective hepatitis C drugs, this roadshow is focused on:
- Showcasing and sharing good practice in the prevention, testing, diagnosis and treatment of hepatitis C
- Identifying specific problems and potential solutions for tackling hepatitis C in the London area, as one of the highest prevalence areas in England
The roadshow will include talks on the commissioning of services, workforce development, awareness and testing, and opportunities for the elimination of hepatitis C as a major public health concern provided by new treatments. Afternoon workshops will be held on specific issues affecting hepatitis C services in London, including on at-risk immigrant communities; awareness and testing in drug services and testing and treatment pathways in prisons.
Registration and coffee will be from 09.00 to 09.55 and the event will run from 10.00 to 15.15. The event will be held at Coin Street Neighbourhood Centre, 108 Stamford Street, London SE1 9NH. The venue is a short walk from Waterloo station. For further details about the venue and to book your place, please visit the event website.
'Together for Health': Welsh Government Liver Disease Delivery Plan
Thursday, 07 May 2015 08:52
The Welsh Government has published its liver disease delivery plan - Together for Health.
It is split into six themes:
- Preventing liver disease and promoting liver health
- Timely detection of liver disease
- Fast and effective care
- Living with liver disease
- Improving information
- Targeting research
For each theme, the following is set out:
- Key service issues
- Specific priorities
- Population outcome indicators and NHS assurance measures
HCV in Cirrhosis - An Update on Treatment Access
Friday, 01 May 2015 11:53
Peter Moss (Chair HCV CRG) & Graham Foster (Vice Chairman HCV CRG)
We are writing to update you on access to treatment for patients with chronic HCV infection. As you know the first review of the Early Access Program was presented at EASL last week. These data show that therapy for patients with decompensated cirrhosis has been very successful and this program will continue.
NHS England has confirmed that access to treatment should be extended, and the CRG have completed a proposal for a new scheme to offer the best available oral antiviral therapy to all patients with cirrhosis. There is a formal sign off step to be completed but we anticipate that the scheme will be up and running by late May. However given the inevitable slippage in delivery times it may be prudent to advise patients that treatment may not commence until early June 2015. The precise details of how treatment will be delivered are still under discussion but we envisage a network approach, and details of centre selection will be circulated as soon as possible, probably within the next 10 days.
BSG supported STOPAH study shows a lack of evidence for drug treatments
Wednesday, 29 April 2015 08:22
The survival of patients with alcohol-related hepatitis is not being significantly improved by the main drugs currently widely used in treatment of this condition, according to a major new National Institute for Health Research sponsored study supported by members of the British Society of Gastroenterology.
Senior health professionals are highlighting an 'urgent need' for investment into research for the prevention and treatment of alcohol-related liver disease. Documented in the New England Journal of Medicine¸ a trial of over 1,000 patients using prednisolone and pentoxifylline did not achieve a statistically significant reduction in mortality after 28 days, 90 days, or a year.
The alarming findings come at a time when the incidence of alcohol-related liver disease is rapidly increasing, however the report does also show that the overall mortality has fallen compared to studies done in the past which suggests that specialist in hospital care of these very sick people can improve outcomes, and what could be achieved more widely contrasting with the 2013 NCEPOD report on the care of cirrhosis where care was often found to be lacking.
Commenting, British Society of Gastroenterology Vice President (Hepatology), Dr Stephen Ryder, said:
"STOPAH has answered some key questions in the treatment of alcohol-related hepatitis and highlighted the urgent need for research into the prevention and treatment of alcohol-related liver disease, which is on the rise.
Whilst the study does suggest that patients are receiving better care than reported in previous reviews, unfortunately it also shows that neither steroids or pentoxifylline are effective treatments and there is no real indication now for their use.
The stark finding in STOPAH remains the high late mortality related to resumption of alcohol intake and emphasises the need for universal implementation of the BSG recommendations on alcohol care teams, that seems likely to be a far more effective intervention than any medical therapy for the acute episode.
One of the great successes of this study was to show that UK hepatologists and gastroenterologists from over 50 UK centres can collaborate to deliver important large scale clinical studies aimed at improving outcomes for patients with liver disease."
Consensus Meeting on Therapy for Chronic Hepatitis C
Friday, 17 April 2015 09:46
London, March 3 2015
The treatment options for patients with chronic hepatitis C are expanding rapidly. To guide clinicians and commissioners the national societies (BASL, BHIVA BIA, BSG, BVHG) representing clinicians with an interest in this area convened a meeting to provide evidence based treatment and management recommendations.
A nominated individual outlined the background data (both published and outcome data from the English early access program) and presented proposals for therapy. These were discussed by the 80 attendees and a consensus was reached. This document outlines the consensus recommendations.
Dr Stephen Ryder, BSG Vice-president Hepatology, April 2015.
Page 3 of 6